19-Oxoandrost-4-ene-3,17-dione amplifies the action of aldosterone.
The amplification of the action of aldosterone by 19-oxoandrost-4-ene-3,17-dione (19-oxo-A-dione) was evaluated by mineralocorticoid bioassays using adrenalectomized rats. Pretreatment of rats with 19-oxo-A-dione did not cause any significant change in urinary Na/K ratio. However, aldosterone caused a significantly lower urinary Na/K ratio and Na excretion in rats pretreated with 19-oxo-A-dione than in rats without pretreatment. These results indicate that the sodium-retaining action of aldosterone is amplified by pretreatment with 19-oxo-A-dione.
Sekihara
H
H
Third Department of Internal Medicine, University of Tokyo, Faculty of Medicine, Japan.
Yazaki
Y
Y
D000315:Adrenalectomy; D000450:Aldosterone / Q000494:pharmacology*; D000735:Androstenedione / Q000031:analogs & derivatives* / Q000494:pharmacology; D000818:Animals; D004357:Drug Synergism; D008297:Male; D011188:Potassium / Q000652:urine; D051381:Rats; D017207:Rats, Sprague-Dawley; D012964:Sodium / Q000652:urine
D000735:Androstenedione; D000450:Aldosterone; C014142:19-oxo-delta(4) androstene-3,17-dione; D012964:Sodium; D011188:Potassium